Efficacy of endovascular treatment of Trans-Atlantic Inter-Society Consensus D aortoiliac occlusive disease

何昊,李全明,黎明,李鑫,舒畅
DOI: https://doi.org/10.3760/cma.j.cn101411-20230119-00006
2023-01-01
Abstract:Objective:To investigate the clinical efficacy and prognosis of endovascular treatment of Trans-Atlantic Inter-Society Consensus D (TASC-D) aortoiliac occlusive disease (AIOD).Methods:A retrospective analysis was made of the clinical data of 115 patients with TASC-D AIOD in the Department of Vascular Surgery of the Second Xiangya Hospital of the Central University from January 2016 to December 2021. Before the operation, a therapeutic protocol was instituted according to Rutherford classification and corresponding imaging examination. All patients underwent endovascular interventions and were followed up regularly. Their clinical symptoms, ankle-brachial index (ABI), complication rate, and patency rate were observed annually.Results:All 115 patients with 148 target vessels underwent endovascular treatment. The overall success rate of endovascular therapy was 98.3% (113/115), and the patency rate of target vessels was 98.6% (146/148). Postoperative Rutherford classification was improved by 4 grades in 4 patients, 3 grades in 58 patients, 2 grades in 24 patients, 1 grade in 1 patient, and no improvement in 28 patients. ABI at one week after the operation was significantly higher than that before the operation [0.9(0.8, 1.1) vs 0.2(0, 0.4), Z=-14.233, P<0.001]. Postoperative complications occurred in 5(4.3%) patients in 30 days. Moreover, 113 patients (144 target vessels ) were followed up with a median follow-up time of 37(21,57) months. The 1-, 3- and 5-year cumulative survival rates were 97.2%, 95.6% and 89.7%, respectively. The 1, 3 and 5 years cumulative freedom from reintervention rates were 90.4%, 86.1% and 83.5%, respectively. The cumulative primary patency rates were 90.4%, 85.2% and 82.5% at 1, 3 and 5 years, respectively. The cumulative secondary patency rates were 92.9% and 85.1% at 1 and 3 years, respectively. Conclusion:Endovascular therapy is safe and effective for TASC-D AIOD with satisfactory mid- and long-term clinical results.
What problem does this paper attempt to address?